-
JACC: Reversal of severe bleeding associated with direct oral anticoagulants
Time of Update: 2021-07-31
Although the effective hemostasis rate of reversal drugs is high, the mortality rate of anticoagulant patients after DOAC-related severe bleeding is still high .
Although the effective hemostasis rate of reversal drugs is high, the mortality rate of anticoagulant patients after DOAC-related severe bleeding is still high .
-
Stroke: Neutrophil count as a promising marker for predicting hospital mortality in patients with aneurysmal subarachnoid hemorrhage
Time of Update: 2021-07-31
It can be seen that in patients with aneurysmal subarachnoid hemorrhage, higher neutrophil counts on admission are associated with mortality and increased risk of hospital-acquired infections .
In patients with aneurysmal subarachnoid hemorrhage, a higher neutrophil count on admission is associated with an increased risk of mortality and hospital-acquired infection .
-
Intensive Care Med: Can viscoelastic hemostasis enhance the survival rate of patients with major traumatic bleeding?
Time of Update: 2021-07-31
Recently, a multi-center randomized controlled trial compared the results of trauma patients receiving empirical MHPs and enhanced them with interventions guided by VHA or CCT .
-
18 cases confirmed in Singapore!
Time of Update: 2021-07-31
An invasive disease called GBS has been found in freshwater fish that are widely eaten in Southeast Asia and can cause Human blood poisoning and meningitisIn 2015, about 146 people fell ill after eating a traditional raw freshwater fish dish in Singapore, and several eventually had to amputate their limbs .
-
JAHA: The use of erythropoietin in hemodialysis patients and the risk of stroke
Time of Update: 2021-07-31
After erythropoietin treatment in patients with end-stage renal disease undergoing hemodialysis, the risk of stroke, ischemic stroke, hemorrhagic stroke, and stroke of unspecified subtypes is not yet clear .
Compared with non-erythropoietin-treated patients, erythropoietin-treated patients did not have an increased risk of ischemic, hemorrhagic, or unspecified subtype stroke (adjusted HR 1.
-
See it soon!
Time of Update: 2021-07-30
study : The individualized treatment guided by PK software can specifically adjust the frequency and dose of FⅧ infusion, reduce bleeding, and improve the quality of life .
-
Nat Med: CAR T cells targeting both CD19 and CD22 to treat relapsed or refractory B-cell malignancies: Phase I trial
Time of Update: 2021-07-30
Therefore, the results of this study further imply that antigen loss is the main cause of CAR T cell resistance , highlighting the challenge that engineered multispecific CAR T cells have the same potency on different targets, and confirming that the production of cytokines is CAR An important quality indicator of T cell potency .
-
Nat Med: Bispecific CAR-T therapy targeting CD19 and CD22 can treat relapsed/refractory B-cell malignancies
Time of Update: 2021-07-30
Previous studies have shown that the anti-tumor effects of chimeric antigen receptor-modified T cells ( CAR-T ) and natural killer (NK) cells targeting CD19 (CAR19) promote the treatment of relapsed/refractory B-cell malignancies Change .
-
J Clin Oncol: The long-term efficacy PK of Acalabrutinib and Ibrutinib for CLL!
Time of Update: 2021-07-30
1%) patients in the Acalabrutinib group and ibrutinib group, respectively, who are still receiving treatment.
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial .
-
J Clin Oncol: Human-derived CD19 CAR T cells can provide lasting remission for patients with relapsed or refractory B-ALL
Time of Update: 2021-07-29
HuCART19 can be used in children and young adults with relapsed or refractory B-ALL to achieve long-lasting remission, including patients who have failed previous CAR T cell therapy.
-
Neurology: the relationship between serum magnesium levels and the risk of intracranial aneurysms
Time of Update: 2021-07-29
Odds ratio resultA higher genetic prediction of serum magnesium concentration is associated with a lower risk of intracranial aneurysm .
It can be seen that the results of this study provide evidence support for increasing the serum magnesium concentration to reduce the risk of intracranial aneurysm and related bleeding .
-
J CEREBR BLOOD FM: Cerebrospinal fluid hemoglobin promotes secondary brain injury related to subarachnoid hemorrhage
Time of Update: 2021-07-29
The relationship between cerebrospinal fluid hemoglobin and secondary brain injury after aneurysmal subarachnoid hemorrhageThere is very strong evidence that there is a positive correlation between CSF-Hb and SAH-SBI measured by spectrophotometry .
In in vitro experiments, the benefits of haptoglobin and heme binding protein make CSF-Hb an attractive biomarker and potential for SAH-SBI treatment.
-
Blood: The incidence of thrombosis in children and adolescents with new coronary pneumonia or MIS-C
Time of Update: 2021-07-28
Multiple system inflammatory syndrome (MIS-C, a post - infection complication) infectionResearchers such as Whitworth conducted a multi-center retrospective cohort study to determine the incidence of thrombosis in hospitalized children with new coronary pneumonia or MIS-C, and to assess related risk factors .
-
Cancer Med: The study found that high BMI and a history of venous thromboembolism are independent risk factors for venous thromboembolism during preoperative chemotherapy in patients with resectable gastric cancer
Time of Update: 2021-07-27
In summary, the results of this study show that high BMI and previous history of VTE are independent risk factors for VTE during preoperative chemotherapy in patients with resectable gastric cancer .
-
Relma-cel shows breakthrough effects for R/R DLBCL patients
Time of Update: 2021-07-27
In view of the mature production technology of CD19 CAR-T targeted by Ruiji Orenza and the excellent clinical data released by the 2020 ASH conference, we believe that Ruiji Orenza will bring new treatment options to China's R/R DLBCL in the future .
-
Chest: The relationship between Covid-19 and the risk of venous thromboembolism
Time of Update: 2021-07-27
Among hospitalized adults of different races, Covid-19 infection increases the risk of VTE, and patient characteristics are associated with a higher risk of thromboembolism in the Covid-19 environment .
-
Nat Cancer: Chemotherapy and mismatch repair defects synergistically promote the occurrence of TP53 mutations and the recurrence of acute lymphoblastic leukemia
Time of Update: 2021-07-27
Synergistically induced TP53 mutation acquisition modelSynergistically induced TP53 mutation acquisition modelAll in all, the results of the study revealed that the TP53 R248Q mutation in recurrent ALL originated from the synergistic effect of thiopurine therapy and MMR deficiency, and proposed strategies to prevent or treat disease recurrence caused by TP53 mutations .
-
JEADV: Evaluation of the efficacy of Mogamulizumab in mycosis fungoides or Sézary syndrome based on baseline blood tumor burden
Time of Update: 2021-07-27
Efficacy and safety of mogamulizumab by patient baseline blood tumour burden: a post hoc analysis of the MAVORIC trial .
17523Efficacy and safety of mogamulizumab by patient baseline blood tumour burden: a post hoc analysis of the MAVORIC trial in this message
-
Nature Sub-Journal: Xu Dong's group reveals a new pathogenesis of Fanconi's anemia
Time of Update: 2021-06-30
On June 10, 2021, Xu Dongyi's group from the School of Life Sciences, Peking University and the State Key Laboratory of Protein and Plant Gene Research published in the journal Nature Structural & Molecular Biology the title: Fanconi anemia proteins participate in a break-induced-replication -like pathway to counter replication stress research paper .
-
J Clin Oncol: Imetelstat, a telomerase inhibitor, can effectively treat myelofibrosis!
Time of Update: 2021-06-28
A phase II multicenter study evaluated the efficacy and safety of Imetelstat in JAKi-R/R myelofibrosis patients with moderate to high risk .
4 mg/kg (1 time/3 weeks) treatment, and JAKi-R/R bone marrow fibers with good safety and adverse risks Patients with chemotherapeutics can obtain clinically beneficial symptom relief rate from Imetelstat 9.
